retatrutide diabetes trial Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Medscape | The investigational triple

The study shows an association, not proof that GLP-1 medicines directly caused every benefit

164 Recently, the Icelandic drug monitoring system reported cases of suicidal ideation and self-harm among patients treated with GLP-1RAs, prompting a review by the European Medicines Agency

Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner

Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as an Add-on to Metformin, Thiazolidinediones, or Both, in Patients With Type 2 Diabetes (SUSTAIN 2): A 56-Week, Double-Blind, Phase 3a, Randomised Trial

Those are parts of the brain like the nucleus accumbens, which is in the basal ganglia, the lizard part of the brain

In addition, ferroptosis, as a form of inflammatory cell death, is associated with the release of DAMPs, which can trigger the innate immune system and activate the NF-B pathway through AGER [95, 109]